Life Science Partner recruits former President and General Manager of the EDX Division of Elan Corporation
Life Science Partner announces the recruitment of John Hannon, an entrepreneurial biopharmaceutical executive, to Exoxemis, Inc. Exoxemis is an early-stage biopharmaceutical research and development company focused on prevention and treatment of serious infections and the significant and growing problem of microbial drug resistance. The company’s myeloperoxidase (MPO) technology is a versatile platform that can be leveraged into multiple product areas, including medical, biodefense, industrial, veterinary, disinfectant, and agricultural applications.
In Hannon’s most recent role at Elan, he was responsible for building the oncology portfolio as well as acquiring complementary products in the fields of sepsis and pain management. He has a broad range of general management, business development, and sales and marketing for healthcare products in the domestic and international markets.
“John has a broad understanding of preparing markets for commercialization of products and proven executive management skills,” noted Tom Callaway, MD, founder and president of Life Science Partner. “Exoxemis will allow him to lead a team in the company’s transformation from a clinical research and product development organization to a commercial company with innovative products to improve and save people’s lives.”
Hannon will direct a talented management team overseeing research and product development, clinical development, operations and sales and marketing.
John received his Graduate Medical Marketing degree from UCLA and his Bachelor of Arts degree from Marquette University in Milwaukee, Wisconsin.